Research and Scholarship

Impact of an Oncology Clinical Pharmacist Intervention on Clinical Trial Enrollment in The US Oncology Network’s MYLUNG Consortium

Elizabeth Koselke,(1), Lisa C. Kaspin-Powell,(2), Shannon Hough,(1), Joshua Howell,(1), Nicholas J. Robert,(2), Marcus A. Neubauer,(3), Susie A. Bullock,(4), Jennifer M. Walberg,(4), Melissa Rammage,(5), James E. Butrynski,(6), David Hakimian,(7), Robert M. Jotte,(8), Michael W. Meshad,(9), Kashif Ali,(10), David Michael Waterhouse,(11), Robert L. Coleman,(4), and Makenzi Colleen Evangelist,(12)

Authors’ disclosures of conflicts of interest are found at the end of this article.

From (1)US Oncology Network, McKesson Specialty Health, The Woodlands, Texas; (2)Ontada, Boston, Massachusetts; (3)US Oncology Research/The US Oncology Network, The Woodlands, Texas; (4)US Oncology Research, The Woodlands, Texas; (5)McKesson Corporation, The Woodlands, Texas; (6)Willamette Valley Cancer Institute, Eugene, Oregon; (7)US Oncology Research/Illinois Cancer Specialists, Niles, Illinois; (8)US Oncology Research/Rocky Mountain Cancer Centers, Lone Tree, Colorado; (9)US Oncology Research/Southern Cancer Center, Daphne, Alabama; (10)US Oncology Research/Maryland Oncology Hematology, Baltimore, Maryland; (11)US Oncology Research/Oncology Hematology Care (OHC), Inc., Cincinnati, Ohio; (12)New York Oncology Hematology, Albany, New York

Introduction: The Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium™ (MYLUNG) clinical trial platform aims to advance the use of precision medicine in patients with non–small cell lung cancer through a series of prospective and iterative clinical trials. Timely patient accrual onto oncology clinical trials is a known practice challenge and impaired accrual rates can lead to premature trial closure or properly powered trial outcomes. The US Oncology Network recently implemented a clinical pharmacist (ClinReview) initiative to provide remote clinical services to screen patients for enrollment onto MYLUNG Protocol 2. This study aims to evaluate the effect of the remote clinical pharmacist intervention on study enrollment rates. Methods: An oncology-trained clinical pharmacist remotely reviewed systemic chemotherapy treatment orders during normal workflow and, in addition, a weekly custom recruitment report within six community Network practices (149 physicians). The pharmacist identified, screened, and assisted with the communication regarding eligible patients for enrollment. The onsite research team received timely and relevant patient data to facilitate expedited enrollment. Enrollment and intervention data were tracked to monitor the impact of the pharmacist intervention. Monthly enrollment was evaluated using a paired t-test. Results: Over 8 months, the pharmacist screened 506 potentially eligible patients; 34% were enrolled. Average monthly enrollment was significantly greater following the ClinReview intervention (3.4 vs. 6.6 patients/month; p = .02). Among the 289 patients not enrolled, 73% exceeded their eligibility window, 9% died or enrolled into hospice, 4% declined participation, and 13% transferred care or were treated at outside facilities. Conclusions: Incorporating an oncology clinical pharmacist into the clinical research team was associated with improved clinical trial enrollment. Validation of the effect of multidisciplinary interventions across a broader spectrum of differentially resourced oncology practices will be conducted within future MYLUNG iterations.

For access to the full length article, please sign in.